You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 8,183,226


✉ Email this page to a colleague

« Back to Dashboard


Title:Myocardial perfusion imaging method
Abstract: The present disclosure provides 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A.sub.2A adenosine receptor, compositions comprising these compounds, and methods for using these compounds in a variety of applications including myocardial perfusion imaging and coronary vasodilation methods. ##STR00001##
Inventor(s): Belardinelli; Luiz (Menlo Park, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:Jan 27, 2010
Application Number:12/695,096
Claims:1. A method of producing coronary vasodilation comprising administering by intravenous (iv) bolus at least 400 micrograms of CVT-3146, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl)pyrazol-4-yl)-N-methylcarboxamide, which has the formula: ##STR00022## to a human in need thereof.

2. The method of claim 1, wherein the CVT-3146 is administered in an amount that does not exceed about 1000 .mu.g.

3. The method of claim 1, wherein the CVT-3146 is administered in a single dose.

4. The method of claim 1, wherein the CVT-3146 is administered in an amount no greater than about 20 .mu.g/kg to a supine patient.

5. The method of claim 1 wherein the CVT-3146 is administered in an amount no greater than about 10 .mu.g/kg to a standing patient.

6. The method of claim 1, wherein the CVT-3146 is administered in about 20 seconds.

7. The method of claim 1, wherein the CVT-3146 is administered in about 10 seconds or less.

8. A method of myocardial perfusion imaging of a human, comprising administering at least 400 micrograms by intravenous (iv) bolus of CVT-3146, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl)pyrazol-4-yl)-N-methylcarboxamide, which has the formula: ##STR00023## and a radionuclide to the human, wherein the myocardium is examined for areas of insufficient blood flow following administration of the CVT-3146 and the radionuclide.

9. The method of claim 8, wherein the myocardium examination begins within about 1 minute from the time the CVT-3146 is administered.

10. The method of claim 8, wherein the administration of the CVT-3146 causes at least a 2.5 fold increase in coronary blood flow.

11. The method of claim 8, wherein the administration of the CVT-3146 causes at least a 2.5 fold increase in coronary blood flow that is achieved within about 1 minute from the administration of the CVT-3146.

12. The method of claim 8, wherein the radionuclide and the CVT-3146 are administered separately.

13. The method of claim 8, wherein the radionuclide and the CVT-3146 are administered simultaneously.

14. The method of claim 8, wherein the administration of the CVT-3146 causes at least a 2.5 fold increase in coronary blood flow for less than about 5 minutes.

15. The method of claim 8, wherein the administration of the CVT-3146 causes at least a 2.5 fold increase in coronary blood flow for less than about 3 minutes.

16. The method of claim 8, wherein the CVT-3146 is administered in a single dose in an amount up to about 600 .mu.g that is independent of the weight of the human being dosed.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.